<?xml version='1.0' encoding='utf-8'?>
<document id="27739231"><sentence text="Phase 1 and Pharmacokinetic Drug-Drug Interaction Study of Metformin, Losartan, and Linagliptin Coadministered With DW1029M in Healthy Volunteers."><entity charOffset="59-68" id="DDI-PubMed.27739231.s1.e0" text="Metformin" /><entity charOffset="70-78" id="DDI-PubMed.27739231.s1.e1" text="Losartan" /><entity charOffset="84-95" id="DDI-PubMed.27739231.s1.e2" text="Linagliptin" /><pair ddi="false" e1="DDI-PubMed.27739231.s1.e0" e2="DDI-PubMed.27739231.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27739231.s1.e0" e2="DDI-PubMed.27739231.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27739231.s1.e0" e2="DDI-PubMed.27739231.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27739231.s1.e1" e2="DDI-PubMed.27739231.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27739231.s1.e1" e2="DDI-PubMed.27739231.s1.e2" /></sentence><sentence text="We investigated botanical drug-pharmaceutical drug interactions between DW1029M (a botanical extract of Morus alba linne root bark and Puerariae radix) and metformin, losartan, and linagliptin in the steady state"><entity charOffset="156-165" id="DDI-PubMed.27739231.s2.e0" text="metformin" /><entity charOffset="167-175" id="DDI-PubMed.27739231.s2.e1" text="losartan" /><entity charOffset="181-192" id="DDI-PubMed.27739231.s2.e2" text="linagliptin" /><pair ddi="false" e1="DDI-PubMed.27739231.s2.e0" e2="DDI-PubMed.27739231.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27739231.s2.e0" e2="DDI-PubMed.27739231.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27739231.s2.e0" e2="DDI-PubMed.27739231.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27739231.s2.e1" e2="DDI-PubMed.27739231.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27739231.s2.e1" e2="DDI-PubMed.27739231.s2.e2" /></sentence><sentence text=" Three studies were conducted as randomized, open-label, 2-period, 2-treatment, multiple-dose, 2-way crossover designs" /><sentence text=" Eligible subjects received metformin (500 mg twice daily), losartan (50 mg once daily), or linagliptin (5 mg once daily) with DW1029M (300 mg × 2T twice daily) every 12 hours on days 1 through 6 and a single dose on the morning of day 7"><entity charOffset="28-37" id="DDI-PubMed.27739231.s4.e0" text="metformin" /><entity charOffset="60-68" id="DDI-PubMed.27739231.s4.e1" text="losartan" /><entity charOffset="92-103" id="DDI-PubMed.27739231.s4.e2" text="linagliptin" /><pair ddi="false" e1="DDI-PubMed.27739231.s4.e0" e2="DDI-PubMed.27739231.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27739231.s4.e0" e2="DDI-PubMed.27739231.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27739231.s4.e0" e2="DDI-PubMed.27739231.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27739231.s4.e1" e2="DDI-PubMed.27739231.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27739231.s4.e1" e2="DDI-PubMed.27739231.s4.e2" /></sentence><sentence text=" Coadministration of DW1029M with metformin, losartan, or linagliptin had no clinically relevant effects based on the area under the plasma concentration-time curve (AUCτ ) geometric least-squares mean ratio (GMR) - AUCτ GMR, 89"><entity charOffset="34-43" id="DDI-PubMed.27739231.s5.e0" text="metformin" /><entity charOffset="45-53" id="DDI-PubMed.27739231.s5.e1" text="losartan" /><entity charOffset="58-69" id="DDI-PubMed.27739231.s5.e2" text="linagliptin" /><pair ddi="false" e1="DDI-PubMed.27739231.s5.e0" e2="DDI-PubMed.27739231.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27739231.s5.e0" e2="DDI-PubMed.27739231.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27739231.s5.e0" e2="DDI-PubMed.27739231.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27739231.s5.e1" e2="DDI-PubMed.27739231.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27739231.s5.e1" e2="DDI-PubMed.27739231.s5.e2" /></sentence><sentence text="7; 90% confidence interval (CI), 81" /><sentence text="0-99" /><sentence text="4 for metformin; AUCτ GMR, 96"><entity charOffset="6-15" id="DDI-PubMed.27739231.s8.e0" text="metformin" /></sentence><sentence text="2; 90%CI, 86" /><sentence text="3-107" /><sentence text="1 for losartan; and AUCτ GMR, 89"><entity charOffset="6-14" id="DDI-PubMed.27739231.s11.e0" text="losartan" /></sentence><sentence text="7; 90%CI, 83" /><sentence text="2-96" /><sentence text="6 for linagliptin"><entity charOffset="6-17" id="DDI-PubMed.27739231.s14.e0" text="linagliptin" /></sentence><sentence text=" In addition, coadministration of DW1029M did not have any clinically meaningful effect on the maximum plasma concentration (Cmax,ss ) - Cmax,ss GMR, 87" /><sentence text="3; 90%CI, 76" /><sentence text="2-100" /><sentence text="0 for metformin; Cmax,ss GMR, 90"><entity charOffset="6-15" id="DDI-PubMed.27739231.s18.e0" text="metformin" /></sentence><sentence text="5; 90%CI, 78" /><sentence text="3-104" /><sentence text="6 for losartan; and Cmax,ss GMR, 81"><entity charOffset="6-14" id="DDI-PubMed.27739231.s21.e0" text="losartan" /></sentence><sentence text="4; 90%CI, 69" /><sentence text="5-95" /><sentence text="3 for linagliptin"><entity charOffset="6-17" id="DDI-PubMed.27739231.s24.e0" text="linagliptin" /></sentence><sentence text=" Coadministration of DW1029M with metformin, losartan, or linagliptin was well tolerated"><entity charOffset="34-43" id="DDI-PubMed.27739231.s25.e0" text="metformin" /><entity charOffset="45-53" id="DDI-PubMed.27739231.s25.e1" text="losartan" /><entity charOffset="58-69" id="DDI-PubMed.27739231.s25.e2" text="linagliptin" /><pair ddi="false" e1="DDI-PubMed.27739231.s25.e0" e2="DDI-PubMed.27739231.s25.e0" /><pair ddi="false" e1="DDI-PubMed.27739231.s25.e0" e2="DDI-PubMed.27739231.s25.e1" /><pair ddi="false" e1="DDI-PubMed.27739231.s25.e0" e2="DDI-PubMed.27739231.s25.e2" /><pair ddi="false" e1="DDI-PubMed.27739231.s25.e1" e2="DDI-PubMed.27739231.s25.e1" /><pair ddi="false" e1="DDI-PubMed.27739231.s25.e1" e2="DDI-PubMed.27739231.s25.e2" /></sentence><sentence text="" /></document>